Netazepide, the gold standard for gastrin/CCK2R (cholecystokinin 2 receptor antagonists), has been tested in multiple trials for treating gastric neuroendocrine tumors and other conditions related to hypergastrinemia [113]. Here, GAST is linked to gastric neuroendocrine tumor, well differentiated, low or intermediate grade.